DBV Technologies S.A. (DBVT) Cut to Hold at Zacks Investment Research
DBV Technologies S.A. (NASDAQ:DBVT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Thursday.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
DBVT has been the subject of several other research reports. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of DBV Technologies in a report on Thursday, July 6th. BidaskClub raised DBV Technologies from a “strong sell” rating to a “sell” rating in a report on Wednesday, June 21st. Deutsche Bank AG assumed coverage on DBV Technologies in a report on Friday, June 23rd. They issued a “buy” rating and a $46.00 price objective for the company. ValuEngine raised DBV Technologies from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Finally, Jefferies Group LLC reissued a “buy” rating on shares of DBV Technologies in a report on Thursday, August 31st. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $50.50.
Shares of DBV Technologies (NASDAQ:DBVT) traded down 0.43% during midday trading on Thursday, hitting $43.84. 38,617 shares of the stock were exchanged. DBV Technologies has a 1-year low of $31.87 and a 1-year high of $46.33. The firm’s market capitalization is $2.02 billion. The stock’s 50-day moving average price is $44.12 and its 200-day moving average price is $37.59.
WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/14/dbv-technologies-s-a-dbvt-cut-to-hold-at-zacks-investment-research-2.html.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd bought a new position in DBV Technologies in the 2nd quarter worth about $222,000. Janus Henderson Group PLC bought a new position in DBV Technologies in the 2nd quarter worth about $90,724,000. Sectoral Asset Management Inc boosted its stake in DBV Technologies by 34.2% in the 2nd quarter. Sectoral Asset Management Inc now owns 179,152 shares of the company’s stock worth $6,398,000 after purchasing an additional 45,653 shares during the period. Airain ltd bought a new position in DBV Technologies in the 2nd quarter worth about $333,000. Finally, Jennison Associates LLC boosted its stake in DBV Technologies by 86.4% in the 2nd quarter. Jennison Associates LLC now owns 1,002,067 shares of the company’s stock worth $35,784,000 after purchasing an additional 464,341 shares during the period. Institutional investors and hedge funds own 45.52% of the company’s stock.
About DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.